- Open Access
Erratum to: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
BMC Neurology volume 11, Article number: 19 (2011)
- The original article was published in BMC Neurology 2009 9:19
In our article , we did not declare some potential competing interests for Prof. Dr. med. Ludwig Kappos:
Declaration of competing interests:
Prof. Dr. med. Ludwig Kappos
LK has participated in the last 24 months as principal investigator, member or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials in multiple sclerosis and other neurological diseases. The sponsoring pharmaceutical companies for these trials include Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, GeNeuro SA, Genmark, GlaxoSmithKline, Lilly, Merck Serono, MediciNova, Novartis, Novonordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB and Wyeth.
I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies.
Honoraria and other payments for all these activities have been exclusively used for funding of research of my department.
Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto, Novartis and Roche Research Foundations.
Nielsen Jessica, Pohl Christoph, Polman Chris, Barkhof Frederik, Freedman Mark, Edan Gilles, Miller David, Bauer Lars, Sandbrink Rupert, Kappos Ludwig, Uitdehaag Bernard: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis. BMC Neurology. 2009, 9: 19-10.1186/1471-2377-9-19.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/11/19/prepub
The online version of the original article can be found at 10.1186/1471-2377-9-19
About this article
Cite this article
Nielsen, J.M., Pohl, C., Polman, C.H. et al. Erratum to: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis. BMC Neurol 11, 19 (2011). https://doi.org/10.1186/1471-2377-11-19